Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
暂无分享,去创建一个
A. Ganser | G. Mufti | N. Kröger | M. Robin | J. Finke | D. Niederwieser | G. Kobbe | A. Symeonidis | J. Cornelissen | L. Volin | M. Bornhäuser | T. Witte | B. Bruno | Y. Chalandon | A. Piciocchi | D. Beelen | L. Wreede | A. Biezen | R. Schwerdtfeger
[1] E. Solary,et al. Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study , 2014 .
[2] E. Solary,et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic‐French Consortium Study , 2014, American journal of hematology.
[3] R. Laborde,et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes , 2013, Leukemia.
[4] D. Birnbaum,et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Arenillas,et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.
[6] L. Arenillas,et al. with chronic myelomonocytic leukemia Development and validation of a prognostic scoring system for patients , 2013 .
[7] H. Deeg,et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] T. Haferlach,et al. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia , 2011, British journal of haematology.
[9] G. Mufti,et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience , 2010, Bone Marrow Transplantation.
[10] D. Weisdorf,et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] O. Haas,et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation , 2008, European journal of clinical investigation.
[12] M. Maris,et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] M. Lübbert,et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). , 2006, Leukemia research.
[14] H. Kantarjian,et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia , 2007, Cancer.
[15] J. Jelinek,et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System , 2007, Leukemia & lymphoma.
[16] S. Ansell,et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia , 2006, Bone Marrow Transplantation.
[17] H. Deeg,et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] S. Karandish,et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia , 2004, Bone Marrow Transplantation.
[19] I. Yakoub-Agha,et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome , 2004, Bone Marrow Transplantation.
[20] N. Kröger,et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia , 2003, Annals of Hematology.
[21] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[22] M. K. Magnússon,et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. , 2002, Blood.
[23] N. Kröger,et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 2002, British journal of haematology.
[24] Terry L. Smith,et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.
[25] J. Bennett,et al. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.
[26] H. Deeg,et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation , 2000, British journal of haematology.
[27] H. Deeg,et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. , 2000, Blood.
[28] A. Gratwohl,et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey , 1998, Bone Marrow Transplantation.
[29] H. van den Berghe,et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. , 1996, Bone marrow transplantation.